Adipotide (FTPP): Peptidomimetic Targeting White Adipose Vasculature
Experimental peptide that selectively destroys blood vessels feeding white fat. Dramatic rodent and monkey results; never advanced in humans for obesity.
🐀 Animal
- Full name
- Adipotide / FTPP (prohibitin-targeting peptidomimetic)
- Class
- Homing peptide–pro-apoptotic chimera
- Half-life
- Short (minutes in circulation)
- Route
- Subcutaneous or intravenous in preclinical studies
- Developer
- Arap & Pasqualini laboratories (academic)
- Regulatory status
- Pre-clinical; no approved use in obesity
What it is
Adipotide is a peptidomimetic consisting of a homing sequence that binds prohibitin (expressed on white-adipose-tissue blood vessels) fused to a pro-apoptotic sequence that triggers endothelial cell death. The concept: selectively prune the vascular supply to white fat.
How it works
Prohibitin is expressed on endothelial cells of white adipose tissue blood vessels. The homing peptide binds prohibitin; the attached KLAKLAK pro-apoptotic motif disrupts mitochondrial membranes and induces apoptosis in those endothelial cells.
Loss of blood supply leads to regression of white adipose tissue. Non-adipose tissue is largely spared because prohibitin localisation is distinct on fat-vessel endothelium.
What the research shows
Pre-clinical efficacy in obese mice and rhesus macaques was striking; a small human cancer trial was the only clinical exposure, and obesity trials were never launched.
Kolonin MG et al. (2004) — first obese-mouse paper
Kolonin M.G. et al., Nat Med 2004;10:625–632. 🐀 Animal
Obese mice received daily subcutaneous injections for 4 weeks.
Body weight fell 30%, adipose mass fell markedly, and metabolic markers improved without effects on non-adipose tissue.
Limitations: Murine data; very short duration.
Barnhart KF et al. (2011) — obese rhesus macaques
Barnhart K.F. et al., Sci Transl Med 2011;3:108ra112. 🐀 Animal
Obese non-human primates received adipotide for 4 weeks.
~11% weight loss, marked reduction in visceral fat, and improved insulin sensitivity. Renal toxicity was observed and required close monitoring.
Limitations: Renal histology changes raised safety concerns for human development; never progressed to obesity trials.
Safety and limitations
The most serious preclinical finding was reversible renal proximal-tubule damage — the principal reason human obesity trials were not initiated. The mechanism may relate to peptide filtration and reabsorption.
Academic interest remains, but regulatory path for obesity appears closed; small trials in cancer patients have been reported with mixed results.